Children with Down syndrome have a much higher risk of leukemia than other children, and the relationship is complex because trisomy 21 changes how blood cells develop from before birth. Two patterns stand out: a unique newborn condition called transient abnormal myelopoiesis (TAM), which can progress to myeloid leukemia of Down syndrome (ML-DS) in early childhood, and a raised risk of acute lymphoblastic leukemia (ALL). Myeloid leukemia in Down syndrome usually responds very well to gentler chemotherapy, while ALL needs careful dose adjustments because these children are more vulnerable to treatment side effects.
For a clinically focused companion piece, see our article on Down syndrome-associated leukemia. Here, I explain why the link exists, what parents should watch for, and how care differs.
Down Syndrome and Leukemia: The Basics
Down syndrome is caused by an extra copy of chromosome 21 (trisomy 21) and occurs in roughly 1 in 700 live births. Leukemia is a cancer of the blood-forming cells in which immature white blood cells multiply uncontrollably and crowd out normal blood production.
Leukemia is still uncommon in children with Down syndrome overall; most never develop it. But the risk is many times higher than in children without Down syndrome, and it is concentrated in the first five years of life. Interestingly, people with Down syndrome have a lower risk of most solid tumors, which underlines how specific the blood connection is.
Why Trisomy 21 Raises Leukemia Risk
A different start to blood formation
Before birth, blood is made mainly in the fetal liver. In fetuses with trisomy 21, the extra copies of chromosome 21 genes push blood cell development toward the megakaryocyte and red cell lines. Genes on chromosome 21 thought to contribute include ERG, RUNX1, and DYRK1A, which influence how blood stem cells grow and specialize.
The GATA1 mutation
In some fetuses, a second change occurs: a mutation in GATA1, a gene on the X chromosome that controls megakaryocyte and red cell maturation. The mutated gene produces a shortened protein, and immature megakaryoblasts accumulate. This combination of trisomy 21 plus a GATA1 mutation is what causes TAM.
Further mutations and progression
TAM usually disappears on its own. In a minority of children, however, the abnormal clone persists, picks up additional mutations (for example in cohesin or signaling genes), and becomes ML-DS, typically before age 4 or 5. ALL in Down syndrome follows a different route. It often involves changes affecting the CRLF2 gene and the JAK-STAT signaling pathway.
Types of Leukemia in Down Syndrome
| Condition | Typical age | Key features | General outlook |
|---|---|---|---|
| Transient abnormal myelopoiesis (TAM) | Newborn, first weeks of life | Blasts in blood; GATA1 mutation; may cause liver enlargement | Usually resolves without treatment within about three months; severe cases need care |
| Myeloid leukemia of Down syndrome (ML-DS) | Usually under 4 to 5 years | Mostly acute megakaryoblastic leukemia; often preceded by TAM | Very responsive to reduced-intensity chemotherapy |
| Acute lymphoblastic leukemia (DS-ALL) | Childhood, often older than ML-DS | Fewer favorable genetic features; CRLF2 changes common | Treatable, but higher risk of treatment toxicity and relapse |
Signs, Symptoms, and Screening
Newborns with Down syndrome usually have a full blood count and blood film in the first days of life to look for TAM. Many babies with TAM have no symptoms. Others show an enlarged liver, jaundice, rash, fluid around the lungs or abdomen, or breathing difficulty.
Symptoms of leukemia later in childhood are similar to those of leukemia in children generally. They arise from bone marrow suppression as leukemia cells take over the bone marrow:
- Tiredness and pallor from anemia
- Easy bruising, petechiae, and nosebleeds from low platelets, sometimes appearing in unusual places such as bruises along the spine
- Frequent or severe infections and unexplained fevers
- Bone or joint pain, and swollen lymph nodes, liver, or spleen
ML-DS may be preceded by months of slowly falling platelet counts. Children with a history of TAM therefore usually have regular blood count checks during the first few years.
Diagnosis and Treatment
Diagnosis
Diagnosis requires a blood count, blood film, and bone marrow examination. Flow cytometry identifies whether the leukemia is myeloid or lymphoid, and genetic testing looks for GATA1 mutations and other changes that guide treatment. In ML-DS, the marrow can be fibrotic and hard to aspirate, so a biopsy may be needed.
Treating TAM
Most babies need only observation. Those with severe symptoms, such as liver dysfunction or very high blast counts, may receive low-dose cytarabine to control the disease.
Treating ML-DS
ML-DS cells are unusually sensitive to chemotherapy, particularly cytarabine. Children receive reduced-intensity regimens designed specifically for Down syndrome, which keep cure rates high while lowering serious side effects. Stem cell transplant is rarely needed in first remission.
Treating DS-ALL
Children with Down syndrome and ALL are treated on standard ALL protocols with modifications. They are more prone to infections, mucositis, and methotrexate toxicity, so doses are adjusted and supportive care, including infection prevention, is intensified. Newer immunotherapies and targeted approaches directed at pathways such as JAK-STAT are areas of active research. For the broader context of the disease, see our leukemia guide.
When to See a Doctor
Contact your child’s doctor promptly for persistent tiredness or paleness, unexplained bruises or tiny red spots on the skin, frequent nosebleeds, recurring fevers or infections, bone pain or limping, or a swollen abdomen. Children with Down syndrome can find it harder to describe symptoms, so changes in behavior, appetite, or activity deserve attention. If your baby had TAM, keep to the recommended follow-up blood tests even if they seem well.
Frequently Asked Questions
Will my child with Down syndrome get leukemia?
Most children with Down syndrome never develop leukemia. The risk is higher than in other children, which is why doctors screen newborns for TAM and stay alert to symptoms in early childhood.
Does TAM always turn into leukemia?
No. TAM resolves on its own in most babies. A minority later develop ML-DS, usually within the first four years, so regular blood count monitoring is recommended after TAM.
Why is chemotherapy reduced for children with Down syndrome?
Children with Down syndrome are more sensitive to some chemotherapy drugs, both the benefits and the side effects. In myeloid leukemia, gentler regimens achieve excellent results, while in ALL, dose modifications and strong supportive care reduce the risk of serious infections and toxicity.
Do adults with Down syndrome have a higher leukemia risk?
The excess risk is concentrated in early childhood. Adults with Down syndrome face other health issues, but the striking leukemia link is mainly a feature of the first years of life.
Key Takeaways
- Trisomy 21 alters fetal blood development, creating fertile ground for leukemia.
- TAM is a newborn condition caused by trisomy 21 plus a GATA1 mutation; it usually resolves but can progress to ML-DS.
- ML-DS responds very well to reduced-intensity chemotherapy, while DS-ALL requires careful dose adjustment.
- Early recognition of symptoms and follow-up after TAM help catch leukemia promptly.
